Meeting
2024 ASCO Breakthrough
Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.
Authors
Xiaofeng Cong
Jilin University, Changchun, China
Xiaofeng Cong , Zijun Xu , Ziling Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Immunotherapies
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 205)
DOI
10.1200/JCO.2024.42.23_suppl.205
Abstract #
205
Poster Bd #
J10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Huiyan Luo
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
First Author: Hu Liang
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jianming Xu
Poster
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.
First Author: Zhongjie Chen